Ser667
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.1
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser667  -  GTF3C1 (human)

Site Information
VRLVRNLsEEGLLRL   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 12260181

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 16 , 17 , 18 ) , mass spectrometry (in vitro) ( 15 )
Disease tissue studied:
breast cancer ( 2 ) , HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, triple negative ( 1 , 2 ) , lung cancer ( 3 ) , non-small cell lung adenocarcinoma ( 3 )
Relevant cell line - cell type - tissue:
293 (epithelial) ( 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 ) , breast ( 1 , 2 ) , HeLa (cervical) ( 5 , 15 ) , HUES-9 ('stem, embryonic') ( 16 ) , Jurkat (T lymphocyte) ( 4 , 6 , 17 , 18 ) , K562 (erythroid) ( 5 ) , lung ( 3 )

Upstream Regulation
Kinases, in vitro:
Chk1 (human) ( 15 )

References 

1

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

2

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

3

Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96
23911959   Curated Info

4

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

5

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

6

Guo A (2012) CST Curation Set: 13866; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

7

Mulhern D (2011) CST Curation Set: 12822; Year: 2011; Biosample/Treatment: cell line, HEK 293/ku-0063794; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) AMPK Substrate (P-S/T(2)-102) Rabbit mAb Cat#: 5759, PTMScan(R) Phospho-AMPK Substrate Motif (LXRXXS*/T*) Immunoaffinity Beads Cat#: 5760
Curated Info

8

Mulhern D (2011) CST Curation Set: 12823; Year: 2011; Biosample/Treatment: cell line, HEK 293/ku-0063794; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) AMPK Substrate (P-S/T(2)-102) Rabbit mAb Cat#: 5759, PTMScan(R) Phospho-AMPK Substrate Motif (LXRXXS*/T*) Immunoaffinity Beads Cat#: 5760
Curated Info

9

Mulhern D (2011) CST Curation Set: 12824; Year: 2011; Biosample/Treatment: cell line, HEK 293/PP242; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) AMPK Substrate (P-S/T(2)-102) Rabbit mAb Cat#: 5759, PTMScan(R) Phospho-AMPK Substrate Motif (LXRXXS*/T*) Immunoaffinity Beads Cat#: 5760
Curated Info

10

Mulhern D (2011) CST Curation Set: 12825; Year: 2011; Biosample/Treatment: cell line, HEK 293/PP242; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) AMPK Substrate (P-S/T(2)-102) Rabbit mAb Cat#: 5759, PTMScan(R) Phospho-AMPK Substrate Motif (LXRXXS*/T*) Immunoaffinity Beads Cat#: 5760
Curated Info

11

Mulhern D (2011) CST Curation Set: 12826; Year: 2011; Biosample/Treatment: cell line, HEK 293/WYE-354; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) AMPK Substrate (P-S/T(2)-102) Rabbit mAb Cat#: 5759, PTMScan(R) Phospho-AMPK Substrate Motif (LXRXXS*/T*) Immunoaffinity Beads Cat#: 5760
Curated Info

12

Mulhern D (2011) CST Curation Set: 12827; Year: 2011; Biosample/Treatment: cell line, HEK 293/WYE-354; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) AMPK Substrate (P-S/T(2)-102) Rabbit mAb Cat#: 5759, PTMScan(R) Phospho-AMPK Substrate Motif (LXRXXS*/T*) Immunoaffinity Beads Cat#: 5760
Curated Info

13

Mulhern D (2011) CST Curation Set: 12828; Year: 2011; Biosample/Treatment: cell line, HEK 293/rapamycin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) AMPK Substrate (P-S/T(2)-102) Rabbit mAb Cat#: 5759, PTMScan(R) Phospho-AMPK Substrate Motif (LXRXXS*/T*) Immunoaffinity Beads Cat#: 5760
Curated Info

14

Mulhern D (2011) CST Curation Set: 12829; Year: 2011; Biosample/Treatment: cell line, HEK 293/rapamycin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) AMPK Substrate (P-S/T(2)-102) Rabbit mAb Cat#: 5759, PTMScan(R) Phospho-AMPK Substrate Motif (LXRXXS*/T*) Immunoaffinity Beads Cat#: 5760
Curated Info

15

Blasius M, et al. (2011) A phospho-proteomic screen identifies substrates of the checkpoint kinase Chk1. Genome Biol 12, R78
21851590   Curated Info

16

Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3
21406692   Curated Info

17

Possemato A (2009) CST Curation Set: 8350; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XX[ST]
Curated Info

18

Possemato A (2009) CST Curation Set: 8351; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XX[ST]
Curated Info